Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells

Frontiers in Endocrinology

Volumn 5, Issue MAY, 2014, Pages

  Zeng, Li ^a   Holly, Jeff M P ^a   Perks, Claire M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Breast cancer; Drug sensitivity; Egcg; Green tea; Physiological

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR ALPHA; GREEN TEA EXTRACT; PROTEIN P53; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; THYMIDINE; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST EPITHELIUM; CANCER CELL; CELL COUNTING; CELL CULTURE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; WESTERN BLOTTING;

EID: 84905506769     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00061     Document Type: Article

References (51)

1. Lecumberri E, Dupertuis YM, Miralbell R, Pichard C. Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin Nutr (2013) 32(6):894-903. doi: 10.1016/j.clnu.2013.03.008
2. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol (2002) 42:25-54. doi:10.1146/annurev.pharmtox.42.082101.154309
3. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer (2003) 3(10):768-80. doi:10.1038/nrc1189
4. Yang CS, Li G, Yang Z, Guan F, Chen A, Ju J. Cancer prevention by tocopherols and tea polyphenols. Cancer Lett (2013) 334(1):79-85. doi:10.1016/j.canlet.2013.01.051
5. Benson JR, Jatoi I. The global breast cancer burden. Future Oncol (2012) 8(6):697-702. doi:10.2217/fon.12.61
6. Lambert JD, Yang CS. Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res (2003) 52(3-524):201-8. doi:10.1016/S0027-5107(02)00336-6
7. Lee MJ, Wang ZY, Li H, Chen L, Sun Y, Gobbo S, et al. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev (1995) 4(4):393-9.
8. Zhou DH, Wang X, Yang M, Shi X, Huang W, Feng Q. Combination of low concentration of (-)-epigallocatechin gallate (EGCG) and curcumin strongly suppresses the growth of non-small cell lung cancer in vitro and in vivo through causing cell cycle arrest. Int J Mol Sci (2013) 14(6):12023-36. doi:10.3390/ijms140612023
9. Relat J, Blancafort A, Oliveras G, Cufi S, Haro D, Marrero PF, et al. Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer. BMC Cancer (2012) 12:280. doi:10.1186/1471-2407-12-280
10. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett (2009) 275(1):86-92. doi:10.1016/j.canlet.2008.10.001
11. Sanchez-Tena S, Vizan P, Dudeja PK, Centelles JJ, Cascante M. Green tea phenolics inhibit butyrate-induced differentiation of colon cancer cells by interacting with monocarboxylate transporter 1. Biochim Biophys Acta (2013) 1832(12):2264-70. doi:10.1016/j.bbadis.2013.08.009
12. Singh T, Katiyar SK. Green tea polyphenol, (-)-epigallocatechin-3-gallate, induces toxicity in human skin cancer cells by targeting beta-catenin signaling. Toxicol Appl Pharmacol (2013) 273(2):418-24. doi:10.1016/j.taap.2013.09.021
13. Belguise K, Guo SQ, Sonenshein GE. Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells. Cancer Res (2007) 67(12):5763-70. doi:10.1158/0008-5472.CAN-06-4327
14. Sen T, Dutta A, Chatterjee A. Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drugs (2010) 21(6):632-44. doi:10.1097/CAD.0b013e32833a4385
15. Gu JW, Makey KL, Tucker KB, Chinchar E, Mao X, Pei I, et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1alpha and NFkappaB, and VEGF expression. Vasc Cell (2013) 5(1):9. doi:10.1186/2045-824X-5-9
16. Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem (2010) 17(20):2141-51. doi:10.2174/092986710791299966
17. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J (2011) 25(4):1198-207. doi:10.1096/fj.10-167924
18. Meeran SM, Patel SN, Chan TH, Tollefsbol TO. A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev Res (2011) 4(8):1243-54. doi:10.1158/1940-6207.CAPR-11-0009
19. Li Y, Yuan YY, Meeran SM, Tollefsbol TO. Synergistic epigenetic reactivation of estrogen receptor-alpha (ERalpha) by combined green tea polyphenol and histone deacetylase inhibitor in ERalpha-negative breast cancer cells. Mol Cancer (2010) 9:274. doi:10.1186/1476-4598-9-274
20. Thomas F, Holly JM, Persad R, Bahl A, Perks CM. Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. Prostate (2010) 70(8):856-65. doi:10.1002/pros.21119
21. Davies SC, Holly JM, Coulson VJ, Cotterill AM, Abdulla AF, Whittaker PG, et al. The presence of cation-dependent proteases for insulin-like growth factor binding proteins does not alter the size distribution of insulin-like growth factors in pregnancy. Clin Endocrinol (1991) 34(6):501-6. doi:10.1111/j.1365-2265.1991.tb00331.x
22. Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC, Schantz SP. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev (1998) 7(4):351-4.
23. Umegaki K, Sugisawa A, Yamada K, Higuchi M. Analytical method of measuring tea catechins in human plasma by solid-phase extraction and HPLC with electrochemical detection. J Nutr Sci Vitaminol (2001) 47(6):402-8. doi:10.3177/jnsv.47.402
24. Lambert JD, Yang CS. Mechanisms of cancer prevention by tea constituents. J Nutr (2003) 133(10):3262S-7S.
25. Howells LM, Moiseeva EP, Neal CP, Foreman BE, Andreadi CK, Sun YY, et al. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin (2007) 28(9):1274-304. doi:10.1111/j.1745-7254.2007.00690.x
26. Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer (2009) 101(9):1606-12. doi:10.1038/sj.bjc.6605335
27. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene (2006) 25(55):7305-10. doi:10.1038/sj.onc.1209735
28. Barnes DM, Camplejohn RS. P53, apoptosis, and breast cancer. J Mammary Gland Biol Neoplasia (1996) 1(2):163-75. doi:10.1007/BF02013640
29. Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci (2011) 12(9):5592-603. doi:10.3390/ijms12095592
30. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res (2008) 41(1):98-107. doi:10.1021/ar700108g
31. Chisholm K, Bray BJ, Rosengren RJ. Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drug (2004) 15(9):889-97. doi:10.1097/00001813-200410000-00010
32. Schramm L. Going green: the role of the green tea component EGCG in chemoprevention. J Carcinog Mutagen (2013) 4(142):1000142. doi:10.4172/2157-2518.1000142
33. Fang MZ, Chen DP, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr (2007) 137(1):223s-8s.
34. Nandakumar V, Vaid M, Katiyar SK. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis (2011) 32(4):537-44. doi:10.1093/carcin/bgq285
35. Berletch JB, Liu C, Love WK, Andrews LG, Katiyar SK, Tollefsbol TO. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J Cell Biochem (2008) 103(2):509-19. doi:10.1002/jcb.21417
36. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate (2001) 46(2):98-107. doi:10.1002/1097-0045(20010201)46:2<98::AID-PROS1013>3.3.CO;2-B
37. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 63(22):7563-70.
38. Liang YC, Lin-Shiau SY, Chen CF, Lin JK. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate. J Cell Biochem (1999) 75(1):1-12. doi:10.1002/(SICI)1097-4644(19991001)75:1<1::AID-JCB1>3.0.CO;2-N
39. De Amicis F, Russo A, Avena P, Santoro M, Vivacqua A, Bonofiglio D, et al. In vitro mechanism for downregulation of ER-alpha expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells. Mol Nutr Food Res (2013) 57(5):840-53. doi:10.1002/mnfr.201200560
40. Zeng L, Jarrett C, Brown K, Gillespie KM, Holly JM, Perks CM. Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells. Exp Cell Res (2013) 319(14):2282-95. doi:10.1016/j.yexcr.2013.06.011
41. Pryzbylkowski P, Obajimi O, Keen JC. Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res Treat (2008) 111(1):15-25. doi:10.1007/s10549-007-9751-0
42. Chang WW, Lin RJ, Yu J, Chang WY, Fu CH, Lai AC, et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res (2013) 15(3):R39. doi:10.1186/bcr3423
43. Fu X, Osborne CK, Schiff R. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast (2013) 22(Suppl 2):S12-8. doi:10.1016/j.breast.2013.08.001
44. Van Aller GS, Carson JD, Tang W, Peng H, Zhao L, Copeland RA, et al. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Biochem Biophys Res Commun (2011) 406(2):194-9. doi:10.1016/j.bbrc.2011.02.010
45. Gunter JH, Sarkar PL, Lubik AA, Nelson CC. New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 2013:834684. doi:10.1155/2013/834684
46. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 14(20):6364-70. doi:10.1158/1078-0432.CCR-07-4879
47. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer (2006) 13(Suppl 1):S33-43. doi:10.1677/erc.1.01280
48. Arteaga CL. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat (1992) 22(1):101-6. doi:10.1007/BF01833338
49. Foulstone EJ, Zeng L, Perks CM, Holly JM. Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology (2013) 154(5):1780-93. doi:10.1210/en.2012-1970
50. Khan N, Bharali DJ, Adhami VM, Siddiqui IA, Cui H, Shabana SM, et al. Oral administration of naturally occurring chitosan based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis (2013) 35(2):415-23. doi:10.1093/carcin/bgt321
51. de Pace RC, Liu X, Sun M, Nie S, Zhang J, Cai Q, et al. Anticancer activities of (-)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. J Liposome Res (2013) 23(3):187-96. doi:10.3109/08982104.2013.788023